Drug Patents in Asia-Pacific: A Country-by-Country Guide to How Long Protection Actually Lasts
The Number Every Pharma Strategist Gets Wrong Ask a pharmaceutical executive how long a drug patent lasts in Asia-Pacific, and […]
Paragraph IV Filings: The Procurement Due Diligence Tool Most Pharma Buyers Ignore
How generic drug suppliers’ litigation histories expose supply chain risk, financial fragility, and competitive staying power — before you sign
Paragraph IV Filings: The Procurement Due Diligence Tool Most Pharma Buyers Ignore Read Post »
Turn Drug Patent Expiry Dates Into Your Next Sales Campaign
A practical playbook for formulation vendors, CDMOs, and excipient suppliers on how to mine patent loss-of-exclusivity data to find, time,
Turn Drug Patent Expiry Dates Into Your Next Sales Campaign Read Post »
Sell the Line Before the Patent Breaks: A Business Development Guide for Solid Dose Equipment & Manufacturing Technology Suppliers Targeting Pre-LOE Generic Expansion
The $200 Billion Window Nobody in Sales Talks About Between 2025 and 2030, an estimated $200 billion in annual branded
The Smarter Monopoly: Orphan Drug Exclusivity vs. Standard Drug Patents
How rare disease drugmakers build market protection that no generic can touch — and what every analyst needs to know
The Smarter Monopoly: Orphan Drug Exclusivity vs. Standard Drug Patents Read Post »
Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic Loss of Exclusivity
The Patent Cliff Is Not an Event. It’s a Calendar. Every biologic drug that ever earned blockbuster status is on
Drug Switching Questions: What Patients Are Really Asking Online
Across hundreds of DrugChatter queries, a clear pattern emerges: patients and caregivers are not just asking about drugs—they’re asking what
Drug Switching Questions: What Patients Are Really Asking Online Read Post »
Beat the Brand: Using Patent Intelligence to Anticipate and Defeat Drug Patent Evergreening
The Evergreening Problem, Defined Precisely Evergreening is not a conspiracy. It is a rational economic strategy executed by legal means,
Squeeze the Patent: How Drug Companies Use Reformulation and New Indications to Outlast Generic Competition
The blockbuster drug model has a built-in expiration date. From the moment a pharmaceutical company files its first patent, the
